

---

# Contents

---

1. Immune Reactions Towards Biopharmaceuticals – a General, Mechanistic Overview .....	1
<i>Camilla Foged and Anne Sundblad</i>	
2. Clinical Aspects of Immunogenicity to Biopharmaceuticals .....	27
<i>Simona Malucchi and Antonio Bertolotto</i>	
3. Assessment of Unwanted Immunogenicity .....	57
<i>Meenu Wadhwa and Robin Thorpe</i>	
4. Models for Prediction of Immunogenicity .....	75
<i>Erwin L. Roggen</i>	
5. Immunogenicity of Biopharmaceuticals: Causes, Methods to Reduce Immunogenicity, and Biosimilars .....	97
<i>Marco van de Weert and Eva Horn Møller</i>	
6. Case Study: Immunogenicity of rhEPO .....	113
<i>Arno Kromminga and Gilbert Deray</i>	
7. Case Study: Immunogenicity of Interferon-Beta .....	127
<i>Klaus Bendtzen and Arno Kromminga</i>	
8. Case Study: Immunogenicity of Insulin .....	137
<i>Henriette Mersebach, Fannie Smith, Thomas Sparre and Lisbeth Bjerring Jensen</i>	
9. Case Study: Immunogenicity of Factor VIII .....	147
<i>Silke Ehrenforth and Stephanie Seremetis</i>	
10. Case Study: Immunogenicity of Natalizumab .....	173
<i>Meena Subramanyam</i>	
11. Case Study: Immunogenicity of Anti-TNF Antibodies .....	189
<i>Klaus Bendtzen</i>	
12. Heparin-Induced Thrombocytopenia .....	205
<i>Carmel A. Celestin and John R. Bartholomew</i>	
13. Presenting an Immunogenicity Risk Assessment to Regulatory Agencies .....	239
<i>Paul Chamberlain</i>	
Subject Index .....	259

Immunogenicity of Biopharmaceuticals

Weert, M.; Møller, E.H. (Eds.)

2008, XII, 266 p., Hardcover

ISBN: 978-0-387-75840-4